Ignite Creation Date:
2024-05-06 @ 9:45 AM
Last Modification Date:
2024-10-26 @ 12:19 PM
Study NCT ID:
NCT03066661
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2019-04-26
First Post:
2017-02-23
Brief Title:
Expanded Access to Entrectinib for Cancers With NTRK123 ROS1 or ALK Gene Fusions
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
Expanded Access to Entrectinib RXDX-101 for the Treatment of Cancers With NTRK ROS1 or ALK Gene Fusions
Status:
NO_LONGER_AVAILABLE
Status Verified Date:
2019-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Expanded access to entrectinib will be given to patients with cancers harboring NTRK123 ROS1 or ALK gene fusions who do not qualify for participation in or who are otherwise unable to access an ongoing clinical trial for entrectinib
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None